InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.54
(
0.00%
)
US TECH 100
17,095.60
(
0.55%
)
Dow Jones
38,475.61
(
-0.07%
)
Brent Oil
87.23
(
-0.39%
)
Bitcoin
64,708.00
(
-2.57%
)
Post# of 251587
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197119

Friday, 06/23/2017 10:12:27 AM

Friday, June 23, 2017 10:12:27 AM

Post# of 251587
(BIIB)—CHMP approves Samsung Bioepis’ Imraldi (Humira FoB):

https://www.wsj.com/articles/samsung-makes-big-play-in-drug-market-with-cheaper-version-of-blockbuster-humira-1498217579

Imraldi will be marketed by BIIB in the EU, Switzerland, Russia, and Turkey (#msg-118427495). MRK holds the commercial rights in the US, where a 351(k) application has not yet been submitted, as far as I know.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up